[Federal Register Volume 83, Number 152 (Tuesday, August 7, 2018)]
[Notices]
[Pages 38710-38711]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-16838]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; telephone: 301-402-5579. A signed

[[Page 38711]]

Confidential Disclosure Agreement may be required to receive any 
unpublished information.

SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 
209 and 37 CFR part 404 to achieve commercialization of results of 
federally-funded research and development.
    Technology description follows.

Albumin Binding Prostate Cancer Treating Compositions

    The invention pertains to a therapeutic agent that includes a 
chemically conjugated residue derived from (((R-)-1-carboxy-2-
mercaptoethyl)carbamoyl)-L-glutamic acid that is further bound to an 
Evans blue analog (EB). The EB analog reversibly binds to circulating 
serum albumin to provide a radiopharmaceutical that retains affinity 
and specificity to prostate specific membrane antigen (PSMA; in this 
case PSMA-617). PSMA is a surface molecule shown to be specifically 
expressed by prostate tumor cells. PSMA expression levels correlate 
with disease stage and with hormone refractory cancers. Although most 
PSMA expression appears to be restricted to the prostate cancer, low 
levels of expression can also be detected in the brain, kidneys, 
salivary glands, and small intestine. The antigen is also shown to be 
expressed by neovascular tumor vessels of multiple other cancers. 
Inclusion of the Evans blue analog promotes high internalization and 
retention rates of the conjugated target ligand, and therefore, higher 
accumulation in PSMA positive tumors. Labeling EB-PSMA-617 derivatives 
with the therapeutic beta emitters, e.g., 90Y, 86Y, and 177Lu gives 
rise to improved tumor response and survival rates.
    Potential Commercial Applications:

 Cancer therapeutics
 Higher stability/Lower toxicity

    Development Stage:

 Early stage

    Inventors: Xiaoyuan Chen and Orit Jacobson Weiss (both of NIBIB).
    Intellectual Property: HHS Reference No. E-054-2018/0; U.S. 
Provisional Patent Applications 62/633,648 filed February 22, 2018.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: July 20, 2018.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-16838 Filed 8-6-18; 8:45 am]
 BILLING CODE 4140-01-P